Does the media favor OMCL or AMN?

In the previous week, Omnicell and Omnicell both had 3 articles in the media. AMN Healthcare Services' average media sentiment score of 0.88 beat Omnicell's score of 0.52 indicating that AMN Healthcare Services is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive AMN Healthcare Services 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OMCL or WST?

In the previous week, West Pharmaceutical Services had 3 more articles in the media than Omnicell. MarketBeat recorded 6 mentions for West Pharmaceutical Services and 3 mentions for Omnicell. West Pharmaceutical Services' average media sentiment score of 0.86 beat Omnicell's score of 0.52 indicating that West Pharmaceutical Services is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive West Pharmaceutical Services 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, OMCL or TFX?

Omnicell has higher earnings, but lower revenue than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omnicell $1.25B 1.20 $2.05M $0.84 39.32 Teleflex $2.25B 2.26 -$905.64M -$23.29 N/A

Is OMCL or TFX more profitable?

Omnicell has a net margin of 3.13% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat Omnicell's return on equity. Company Net Margins Return on Equity Return on Assets Omnicell 3.13% 5.66% 3.57% Teleflex -39.67% 11.93% 5.44%

Does the media favor OMCL or TFX?

In the previous week, Omnicell and Omnicell both had 3 articles in the media. Omnicell's average media sentiment score of 0.52 beat Teleflex's score of 0.47 indicating that Omnicell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Teleflex 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, OMCL or HAE?

Haemonetics has higher revenue and earnings than Omnicell. Omnicell is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omnicell $1.25B 1.20 $2.05M $0.84 39.32 Haemonetics $1.35B 3.57 $97.31M $2.04 52.03

Is OMCL or HAE more profitable?

Haemonetics has a net margin of 7.12% compared to Omnicell's net margin of 3.13%. Haemonetics' return on equity of 27.55% beat Omnicell's return on equity. Company Net Margins Return on Equity Return on Assets Omnicell 3.13% 5.66% 3.57% Haemonetics 7.12% 27.55% 9.65%

Does the media refer more to OMCL or HAE?

In the previous week, Haemonetics had 2 more articles in the media than Omnicell. MarketBeat recorded 5 mentions for Haemonetics and 3 mentions for Omnicell. Haemonetics' average media sentiment score of 0.76 beat Omnicell's score of 0.52 indicating that Haemonetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, OMCL or LIVN?

Omnicell has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omnicell $1.25B 1.20 $2.05M $0.84 39.32 LivaNova $1.47B 2.82 -$242.47M $3.38 22.32

Is OMCL or LIVN more profitable?

LivaNova has a net margin of 12.82% compared to Omnicell's net margin of 3.13%. LivaNova's return on equity of 16.35% beat Omnicell's return on equity. Company Net Margins Return on Equity Return on Assets Omnicell 3.13% 5.66% 3.57% LivaNova 12.82% 16.35% 7.76%

Does the media favor OMCL or LIVN?

In the previous week, LivaNova had 1 more articles in the media than Omnicell. MarketBeat recorded 4 mentions for LivaNova and 3 mentions for Omnicell. Omnicell's average media sentiment score of 0.52 beat LivaNova's score of 0.46 indicating that Omnicell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Omnicell (OMCL) Competitors

$33.03 +0.04 (+0.12%)

Closing price 04:00 PM Eastern

Extended Trading

$33.01 -0.02 (-0.06%)

As of 06:11 PM Eastern

Compare

OMCL vs. AMN, WST, TFX, HAE, and LIVN

Should you buy Omnicell stock or one of its competitors? Omnicell's main competitors and comparable companies include AMN Healthcare Services (AMN), West Pharmaceutical Services (WST), Teleflex (TFX), Haemonetics (HAE), and LivaNova (LIVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Omnicell compare to AMN Healthcare Services?

Omnicell (NASDAQ:OMCL) and AMN Healthcare Services (NYSE:AMN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Omnicell has a net margin of 3.13% compared to AMN Healthcare Services' net margin of 3.06%. AMN Healthcare Services' return on equity of 19.92% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	3.13%	5.66%	3.57%
AMN Healthcare Services	3.06%	19.92%	5.93%

Omnicell currently has a consensus target price of $57.86, indicating a potential upside of 75.17%. AMN Healthcare Services has a consensus target price of $36.00, indicating a potential upside of 4.01%. Given Omnicell's stronger consensus rating and higher possible upside, analysts plainly believe Omnicell is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
AMN Healthcare Services	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

97.7% of Omnicell shares are owned by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are owned by institutional investors. 2.9% of Omnicell shares are owned by company insiders. Comparatively, 1.1% of AMN Healthcare Services shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Omnicell has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

Omnicell has higher earnings, but lower revenue than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.25B	1.20	$2.05M	$0.84	39.32
AMN Healthcare Services	$3.43B	0.39	-$95.70M	$2.68	12.92

In the previous week, Omnicell and Omnicell both had 3 articles in the media. AMN Healthcare Services' average media sentiment score of 0.88 beat Omnicell's score of 0.52 indicating that AMN Healthcare Services is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
AMN Healthcare Services	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Omnicell beats AMN Healthcare Services on 9 of the 15 factors compared between the two stocks.

How does Omnicell compare to West Pharmaceutical Services?

Omnicell (NASDAQ:OMCL) and West Pharmaceutical Services (NYSE:WST) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Omnicell has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

West Pharmaceutical Services has higher revenue and earnings than Omnicell. Omnicell is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.25B	1.20	$2.05M	$0.84	39.32
West Pharmaceutical Services	$3.33B	7.92	$493.70M	$7.81	47.95

97.7% of Omnicell shares are held by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are held by institutional investors. 2.9% of Omnicell shares are held by insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, West Pharmaceutical Services had 3 more articles in the media than Omnicell. MarketBeat recorded 6 mentions for West Pharmaceutical Services and 3 mentions for Omnicell. West Pharmaceutical Services' average media sentiment score of 0.86 beat Omnicell's score of 0.52 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
West Pharmaceutical Services	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

West Pharmaceutical Services has a net margin of 16.98% compared to Omnicell's net margin of 3.13%. West Pharmaceutical Services' return on equity of 20.11% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	3.13%	5.66%	3.57%
West Pharmaceutical Services	16.98%	20.11%	14.83%

Omnicell presently has a consensus price target of $57.86, indicating a potential upside of 75.17%. West Pharmaceutical Services has a consensus price target of $382.00, indicating a potential upside of 2.00%. Given Omnicell's higher probable upside, analysts plainly believe Omnicell is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
West Pharmaceutical Services	0 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

West Pharmaceutical Services beats Omnicell on 13 of the 16 factors compared between the two stocks.

How does Omnicell compare to Teleflex?

Omnicell (NASDAQ:OMCL) and Teleflex (NYSE:TFX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

97.7% of Omnicell shares are held by institutional investors. Comparatively, 95.6% of Teleflex shares are held by institutional investors. 2.9% of Omnicell shares are held by company insiders. Comparatively, 0.7% of Teleflex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Omnicell and Omnicell both had 3 articles in the media. Omnicell's average media sentiment score of 0.52 beat Teleflex's score of 0.47 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Teleflex	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Omnicell has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Teleflex has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

Omnicell has higher earnings, but lower revenue than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.25B	1.20	$2.05M	$0.84	39.32
Teleflex	$2.25B	2.26	-$905.64M	-$23.29	N/A

Omnicell has a net margin of 3.13% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	3.13%	5.66%	3.57%
Teleflex	-39.67%	11.93%	5.44%

Omnicell presently has a consensus target price of $57.86, indicating a potential upside of 75.17%. Teleflex has a consensus target price of $152.90, indicating a potential upside of 27.25%. Given Omnicell's stronger consensus rating and higher probable upside, equities analysts clearly believe Omnicell is more favorable than Teleflex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Teleflex	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

Summary

Omnicell beats Teleflex on 11 of the 16 factors compared between the two stocks.

How does Omnicell compare to Haemonetics?

Omnicell (NASDAQ:OMCL) and Haemonetics (NYSE:HAE) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Omnicell presently has a consensus target price of $57.86, suggesting a potential upside of 75.17%. Haemonetics has a consensus target price of $99.78, suggesting a potential downside of 5.99%. Given Omnicell's stronger consensus rating and higher probable upside, research analysts plainly believe Omnicell is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

Haemonetics has higher revenue and earnings than Omnicell. Omnicell is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.25B	1.20	$2.05M	$0.84	39.32
Haemonetics	$1.35B	3.57	$97.31M	$2.04	52.03

Haemonetics has a net margin of 7.12% compared to Omnicell's net margin of 3.13%. Haemonetics' return on equity of 27.55% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	3.13%	5.66%	3.57%
Haemonetics	7.12%	27.55%	9.65%

Omnicell has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Haemonetics has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

In the previous week, Haemonetics had 2 more articles in the media than Omnicell. MarketBeat recorded 5 mentions for Haemonetics and 3 mentions for Omnicell. Haemonetics' average media sentiment score of 0.76 beat Omnicell's score of 0.52 indicating that Haemonetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.7% of Omnicell shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 2.9% of Omnicell shares are owned by company insiders. Comparatively, 2.1% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Haemonetics beats Omnicell on 12 of the 17 factors compared between the two stocks.

How does Omnicell compare to LivaNova?

Omnicell (NASDAQ:OMCL) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

97.7% of Omnicell shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 2.9% of Omnicell shares are owned by insiders. Comparatively, 0.4% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

LivaNova has a net margin of 12.82% compared to Omnicell's net margin of 3.13%. LivaNova's return on equity of 16.35% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	3.13%	5.66%	3.57%
LivaNova	12.82%	16.35%	7.76%

Omnicell has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

Omnicell currently has a consensus price target of $57.86, indicating a potential upside of 75.17%. LivaNova has a consensus price target of $84.13, indicating a potential upside of 11.51%. Given Omnicell's stronger consensus rating and higher possible upside, research analysts clearly believe Omnicell is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55

In the previous week, LivaNova had 1 more articles in the media than Omnicell. MarketBeat recorded 4 mentions for LivaNova and 3 mentions for Omnicell. Omnicell's average media sentiment score of 0.52 beat LivaNova's score of 0.46 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Omnicell has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.25B	1.20	$2.05M	$0.84	39.32
LivaNova	$1.47B	2.82	-$242.47M	$3.38	22.32

Summary

Omnicell beats LivaNova on 9 of the 16 factors compared between the two stocks.

Get Omnicell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OMCL vs. The Competition

Export

Metric	Omnicell	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.50B	$5.49B	$7.26B	$13.10B
Dividend Yield	N/A	1.79%	2.52%	12.57%
P/E Ratio	39.32	25.36	274.98	25.77
Price / Sales	1.20	89.55	679.25	97.61
Price / Cash	11.99	33.02	77.80	52.76
Price / Book	1.20	5.74	10.52	6.34
Net Income	$2.05M	$151.55M	$3.49B	$360.00M
7 Day Performance	1.26%	-0.36%	-1.08%	-0.11%
1 Month Performance	-4.70%	-3.98%	-3.39%	-3.42%
1 Year Performance	6.96%	5.74%	15.08%	5.46%

Omnicell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OMCL Omnicell	3.9 of 5 stars	$33.03 +0.1%	$57.86 +75.2%	+6.4%	$1.50B	$1.25B	39.32	3,580
AMN AMN Healthcare Services	1.9817 of 5 stars	$34.16 +2.5%	$36.00 +5.4%	+83.8%	$1.29B	$2.73B	12.75	2,664
WST West Pharmaceutical Services	3.2614 of 5 stars	$355.74 +2.7%	$379.08 +6.6%	+49.7%	$24.37B	$3.33B	45.55	10,800	Analyst Upgrade
TFX Teleflex	4.386 of 5 stars	$130.36 -0.5%	$152.90 +17.3%	-0.1%	$5.55B	$1.99B	N/A	15,500	Positive News Analyst Forecast
HAE Haemonetics	2.3665 of 5 stars	$106.16 +3.4%	$99.78 -6.0%	+111.5%	$4.67B	$1.33B	52.04	3,009

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OMCL) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omnicell (OMCL) Competitors

OMCL vs. AMN, WST, TFX, HAE, and LIVN

How does Omnicell compare to AMN Healthcare Services?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Summary

How does Omnicell compare to Teleflex?

Summary

How does Omnicell compare to Haemonetics?

Summary

How does Omnicell compare to LivaNova?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omnicell (OMCL) Competitors

OMCL vs. AMN, WST, TFX, HAE, and LIVN

How does Omnicell compare to AMN Healthcare Services?

Is OMCL or AMN more profitable?

Do analysts recommend OMCL or AMN?

Do institutionals and insiders believe in OMCL or AMN?

Which has more risk and volatility, OMCL or AMN?

Which has stronger earnings and valuation, OMCL or AMN?

Does the media favor OMCL or AMN?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Which has more volatility & risk, OMCL or WST?

Which has stronger earnings & valuation, OMCL or WST?

Do institutionals & insiders believe in OMCL or WST?

Does the media favor OMCL or WST?

Is OMCL or WST more profitable?

Do analysts prefer OMCL or WST?

Summary

How does Omnicell compare to Teleflex?

Do insiders & institutionals believe in OMCL or TFX?

Does the media favor OMCL or TFX?

Which has more risk & volatility, OMCL or TFX?

Which has preferable earnings and valuation, OMCL or TFX?

Is OMCL or TFX more profitable?

Do analysts recommend OMCL or TFX?

Summary

How does Omnicell compare to Haemonetics?

Do analysts rate OMCL or HAE?

Which has better earnings & valuation, OMCL or HAE?

Is OMCL or HAE more profitable?

Which has more risk & volatility, OMCL or HAE?

Does the media refer more to OMCL or HAE?

Do insiders and institutionals hold more shares of OMCL or HAE?

Summary

How does Omnicell compare to LivaNova?

Do institutionals and insiders believe in OMCL or LIVN?

Is OMCL or LIVN more profitable?

Which has more risk and volatility, OMCL or LIVN?

Do analysts rate OMCL or LIVN?

Does the media favor OMCL or LIVN?

Which has better valuation and earnings, OMCL or LIVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools